Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COLUMN
COLUMN
- When Interviewing, Share the Love
March 27, 2015
- Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
- Eliminating Bias from the Interview Process
January 23, 2015
- Loss Aversion: Why Candidates Reject Offers
December 26, 2014
- What You Don’t Know About Communication Can Hurt You
November 28, 2014
- 3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
- Successful People Have the Best Information
September 24, 2014
- Is Your Body Language Louder than Your Speech?
August 25, 2014
- Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
- It’s Moments Like These
June 27, 2014
- How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
- Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
- Emerging Immunotherapy of Cancer: 2
April 11, 2014
- Emerging Immunotherapy of Cancer: 1
April 10, 2014
- Sun Tzu and the Art of Interviewing
March 18, 2014
- 2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
- The Time Is Now for Medical Affairs
January 17, 2014
- Blue Ocean Recruiting
December 20, 2013
- Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…